Skip to main content
. 2020 May 25;25(10):2454. doi: 10.3390/molecules25102454

Figure 5.

Figure 5

The combined treatment inhibits the activation of Akt/mTOR signaling pathway in the HCC cells. The panels indicate Western blot analysis for phosphorylation and total protein levels of the members of the Akt/mTOR pathway in the HCC cells treated with BEZ235 and regorafenib for 48 h.